Business
Block Listing Application to AIM (update)
Block Listing Application to AIM (update).
About this update from Avacta Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5273K\n Avacta Group PLC\n 06 May 2022\n \n \n \n \n \n \n \n 06 May 2022\n \n \n \n \n \n Avacta Group plc\n \n \n \n \n \n (\"Avacta\" or \"the Group\" or \"the Company\")\n \n \n \n \n \n Block Listing Application to AIM (update)\n \n \n \n \n \n Avacta Group plc (AIM: AVCT), a clinical stage oncology company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms\n , today announces that further to the announcement made on 28 April 2022 regarding the application to AIM for a block listing of 2,000,000 ordinary shares of 10 pence each in the Company, the block listing is expected to become effective on or around 9 May 2022\n . \n \n \n \n \n \n \n - \n \n \n Ends -\n \n \n \n \n \n \n \n \n \n \n \n \n For further information from Avacta Group plc, please contact:\n \n \n \n \n \n \n \n \n Avacta Group plc\n \n \n Alastair Smith, Chief Executive Officer\n \n \n Tony Gardiner, Chief Financial Officer\n \n \n Michael Vinegrad, Group Communications Director\n \n \n \n \n \n \n \n \n \n \n Tel: +44 (0) 844 414 0452\n \n \n \n \n www.avacta.com\n \n \n \n \n \n \n \n \n \n \n \n Stifel Nicolaus Europe Limited (Nomad and Broker)\n \n \n Nicholas Moore / Nick Adams / Fred Walsh / Nicholas Harland\n \n \n \n \n \n \n \n Tel: +44 (0) 207 710 7600\n \n \n \n \n www.stifel.com\n \n \n \n \n \n \n \n \n \n \n \n FTI Consulting (Financial Media and IR)\n \n \n Simon Conway / Alex Shaw\n \n \n \n \n \n \n \n Tel: +44(0) 203 727 1000\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n Zyme Communications \n \n (Trade and Regional Media)\n \n \n Lily Jeffery\n \n \n \n \n \n \n \n Tel: +44 (0)7787 502 947\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n About Avacta Group plc - \n \n \n \n https://www.avacta.com\n \n \n \n \n \n \n \n Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.\n \n \n \n \n \n The Affimer® platform is an alternative to antibodies and is derived from a small human protein. Affimer®...